Category: Baxter InternationalSyndicate content

China halts anti-dumping probe into EU, Japan dialysis kit makers

December 17, 2014 by MassDevice

China closes out an anti-dumoing probe into foreign dialysis kit makers including Fresenius, Nikkiso and Nipro.

China halts anti-dumping probe into EU, Japan dialysis kit makers

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Baxter IV container recall is Class I

November 21, 2014 by Mark Hollmer

The FDA slaps a Class I recall label on Baxter International's pullback of tainted containers used to prepare intravenous medicines.

Baxter IV container recall is Class I

Baxter's (NYSE:BAX) recall of tainted containers used to prepare intravenous medicines is drawing heightened FDA scrutiny. The regulatory agency slapped a Class I label on the effort, its most serious designation.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtech's betting on the GOP in midterm elections

October 24, 2014 by Brian Johnson

A look at the top 10 politicial action committee donations shows that medtech is betting heavily on a GOP win in the midterm elections.

Medtech's betting on the GOP in midterm elections

The medical device industry is betting on a Republican sweep of the U.S. Congress during the 2014 mid term elections, according to a MassDevice.com analysis of donations made by the industry's 10 largest political action committees.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medical products push Baxter profit above estimate

October 16, 2014 by MassDevice

Baxter's 3rd-quarter profits beat expectations, driven by its medical product business, but shares slide on a lowered earnings forecast.

Medical products push Baxter profit above estimate

(Reuters) - Medical device and drug maker Baxter (NYSE:BAX) reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Baxter biopharm spinout Baxalta's R&D is Cambridge-bound

September 30, 2014 by Alex Soule

Baxter International confirmed Cambridge, Mass., as the new R&D hub for Baxalta, the planned spinout of its biopharmaceuticals business.

Baxter biopharm spinout Baxalta's R&D is Cambridge-bound

Baxter names its pharma spinout: Baxalta

September 11, 2014 by Arezu Sarvestani

Baxter's has 'high' hopes for its coming Baxalta spinout, which will get a full visual work-up before the company goes live mid-2015.

Baxter names its pharma spinout: Baxalta

Baxter (NYSE:BAX) crept a little closer to spinning out its biopharmaceuticals division into an independent entity by giving the company a name: Baxalta.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Failure of Medtronic's Symplicity-3 trial doesn't mean the end of renal denervation for hypertension | Medtech Wall Street news for the week of September 1, 2014

September 4, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Renal denervation isn't dead, despite Medtronic trial's failure; Baxter says HQ will stay in Illinois, stays coy on Boston plans; Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello